WVE-007 is one shot. 85 days. 9.4% less visceral fat. 3.2% more muscle.
It's Wave Life Sciences' investigational obesity drug, technically an RNA interference (RNAi) therapy rather than a peptide, but it's gotten the "James Bond peptide" nickname after Mark Bell's viral podcast appearance with Danny Jones. The drug targets the INHBE gene, sometimes called the "James Bond gene" because humans born with naturally low INHBE have built-in protection against visceral fat gain. WVE-007 mimics that genetic advantage with a single subcutaneous injection that may only need to be repeated once or twice per year. Below is what WVE-007 actually is, the Phase 1 trial data from late 2025, how it compares to GLP-1s like Ozempic and Zepbound, and the honest timeline for when (or whether) it'll be available.
🔑 Key Takeaways
- WVE-007 is not actually a peptide. It's a GalNAc-siRNA, an RNA interference therapy. The "peptide" nickname is media simplification; the science is different.
- One shot, lasting months. Phase 1 data showed greater than 75% suppression of the target biomarker (Activin E) maintained 85 days after a single 240 mg injection.
- It builds muscle while burning fat. The single most important differentiator from GLP-1s: 3.2% lean mass gain instead of the 25-40% muscle loss typical on tirzepatide or semaglutide.
- The "James Bond" name comes from genetics, not Bond films. Humans born with low-INHBE variants are naturally protected against visceral fat accumulation. WVE-007 mimics this protective genetic profile in everyone else.
- Not available yet, and won't be for years. Phase 1 → Phase 2 → Phase 3 → FDA approval typically takes 4-6 years from current stage. Plan for 2028-2030 commercial availability at the earliest.
What Is WVE-007?
WVE-007 is an investigational obesity drug developed by Wave Life Sciences (Nasdaq: WVE), a clinical-stage biotechnology company specializing in RNA-based medicines. Technically, it's a GalNAc-conjugated siRNA, a synthetic small interfering RNA molecule attached to a sugar (N-acetylgalactosamine) that targets the drug to the liver, where it silences the gene that produces a hormone called Activin E. It's administered as a single subcutaneous injection.
The "peptide" label widely used in podcasts, X posts, and media coverage is technically wrong. WVE-007 is an RNAi therapy, not a chain of amino acids. The reason it gets called a peptide anyway is that the broader "GLP-1 / weight-loss injection" category has been dominated by peptide drugs (semaglutide, tirzepatide, retatrutide) for the past three years, so any new injectable weight-loss compound is loosely called a peptide in popular conversation.
It's currently being evaluated in the INLIGHT Phase 1 trial (ClinicalTrials.gov NCT06842186), an open-label and placebo-controlled study of single ascending doses in adults with overweight or obesity. Initial interim data was announced October-December 2025; further data updates expected through 2026.
Why "James Bond Peptide"?
The nickname has two layers, and neither has anything to do with Daniel Craig.
Layer 1: The INHBE gene is the "James Bond gene." Roughly 1 in 200 humans carries a natural loss-of-function variant in the INHBE gene that significantly reduces their body's production of Activin E. People with this variant tend to have a "lean phenotype": healthier waist-to-hip ratios, less visceral fat, better cardiometabolic markers, and they appear to be born resistant to the typical pattern of fat accumulation around the abdomen. They have natural built-in protection, like 007 with his license to kill and seemingly limitless tolerance for martinis. Researchers nicknamed INHBE the "James Bond gene" because of this.
Layer 2: Mark Bell on the Danny Jones Podcast. The viral moment that put "James Bond peptide" into mainstream search traffic was strength coach Mark Bell discussing WVE-007 on the Danny Jones Podcast in late 2025. His pitch was that this could be the long-awaited weight-loss drug that doesn't burn muscle, which is the single biggest unsolved problem of the GLP-1 era. The clip went viral on X and YouTube; "James Bond peptide" became a search trend.
Beyond the nickname's catchiness, the underlying biology is real: WVE-007 is designed to recreate the natural advantage that low-INHBE carriers have, in people who weren't born with it.
How WVE-007 Works
The mechanism is genuinely novel for the obesity space.
- You inject WVE-007 subcutaneously. The GalNAc sugar attached to the siRNA molecule directs the drug to hepatocytes (liver cells), where the INHBE gene is mostly expressed.
- Inside the hepatocyte, the siRNA binds INHBE mRNA and tags it for degradation. The gene is still there; the messenger RNA that would normally tell cells to produce Activin E gets destroyed before it can be translated.
- Activin E production drops dramatically. Phase 1 data showed up to 78% reduction in serum Activin E after a single dose.
- Lower Activin E changes how fat tissue behaves. Activin E normally signals fat-storage and visceral-adipose accumulation. Suppressing it shifts the body toward fat loss, particularly the metabolically harmful visceral fat.
- Muscle is not affected by this signaling pathway. Unlike GLP-1 drugs that suppress appetite (and therefore reduce protein intake and muscle building), WVE-007 doesn't touch appetite or muscle protein synthesis. Lean mass is preserved or increased.
- The siRNA persists for months. Because GalNAc-siRNA chemistry produces durable mRNA suppression, a single injection's effect lasts 85+ days, with the potential for once or twice yearly dosing in clinical use.
WVE-007 Phase 1 Trial Data (INLIGHT)
Wave Life Sciences released interim data from the lowest therapeutic cohort of the INLIGHT Phase 1 trial in October-December 2025. Highlights:
| Metric | Result (240 mg dose, Day 85, vs placebo) |
|---|---|
| Visceral fat reduction (DEXA-measured) | 9.4% (p=0.02) |
| Lean mass change | +3.2% (+4.0 lbs; p=0.01) |
| Total body fat reduction | 4.5% (-3.5 lbs; p=0.07) |
| Total body weight change | -0.9% (modest; muscle gain offset fat loss) |
| Maximum Activin E suppression (biomarker) | 78% post-dose |
| Activin E suppression at Day 85 | Greater than 75% (durable) |
| Mean baseline BMI of subjects | 32 kg/m² |
| Doses tested for safety | Up to 600 mg single dose |
| Discontinuations or serious adverse events | None |
| Liver function or lipid changes | None clinically meaningful |
The 9.4% visceral fat reduction is the headline number, and it's significant. Visceral fat (the fat surrounding internal organs) is the metabolically dangerous kind, the kind that drives insulin resistance, fatty liver, and cardiovascular risk. Reducing it 9.4% from a single shot, while simultaneously building muscle, is unlike anything else in the obesity drug pipeline.
The 0.9% total body weight change deserves context: this is intentionally modest because lean mass gains offset fat losses. The composition shift (fat down, muscle up) is what matters for cardiometabolic health, not the scale number.
Next data update expected: Q1 2026, including 6-month follow-up from the 240 mg cohort and 3-month follow-up from the 400 mg cohort.
WVE-007 vs GLP-1s (Tirzepatide, Semaglutide)
The whole reason WVE-007 is getting attention is the muscle question. Here's the honest comparison.
| Factor | WVE-007 (RNAi) | Tirzepatide / Semaglutide (GLP-1) |
|---|---|---|
| Mechanism | Silences INHBE gene → suppresses Activin E hormone | Activates GLP-1 (and GIP for tirzepatide) receptors |
| Drug class | GalNAc-conjugated siRNA (RNA interference) | Peptide drug |
| Dosing frequency | 1 injection every 6-12 months (potential) | Weekly subcutaneous injection |
| Appetite effect | None | Strong suppression |
| Muscle effect | +3.2% lean mass gain (Phase 1 data) | 25-40% of total weight loss is typically lean muscle |
| Visceral fat loss | 9.4% in 3 months (single dose) | Substantial over 12+ months of weekly use |
| Total weight loss magnitude | Modest (0.9% at 3 months; composition-focused) | 15-22% at 72 weeks at max dose |
| GI side effects | None reported in Phase 1 | Nausea, vomiting, diarrhea (common) |
| FDA status | Phase 1 investigational; not approved | FDA-approved (Mounjaro 2022, Zepbound 2023) |
| Cost (when available) | TBD; expected premium pricing typical of novel biologics | $200-1,300/month depending on source |
| Best for | Body composition optimization, muscle-preserving fat loss (theoretical) | Major weight loss; established efficacy and access today |
The honest take: WVE-007 isn't trying to replace GLP-1s. It's trying to solve the muscle-loss problem that GLP-1s have. The most likely real-world use case (per Wave's own Phase 2 plans) is as an add-on to GLP-1 therapy or as maintenance therapy after stopping a GLP-1, when the patient is at risk of regaining fat while losing the muscle they built. WVE-007 won't be replacing tirzepatide for the average overweight adult. It might end up being a once-yearly muscle-preservation booster for people in the long-term weight-management phase.
When Will WVE-007 Be Available?
Not soon. Realistic timeline:
| Year | Expected milestone |
|---|---|
| 2025 (done) | Phase 1 INLIGHT trial initiated; interim data from 240 mg cohort |
| Q1 2026 | Additional Phase 1 data: 6-month follow-up (240 mg), 3-month follow-up (400 mg) |
| Mid-late 2026 | Phase 1 completion; Phase 2 design and initiation |
| 2027-2028 | Phase 2 trial completion; Phase 3 trial start |
| 2028-2030 | Phase 3 trial completion; FDA review; potential approval |
| 2030+ | Potential commercial availability |
This timeline assumes everything proceeds smoothly. Drug development typically loses 80%+ of candidates between Phase 1 and approval. WVE-007's early safety profile and clean mechanism are encouraging, but assume nothing.
The only way to access WVE-007 today is to enroll in the INLIGHT trial through Wave Life Sciences. Eligibility is limited to adults with overweight or obesity meeting specific criteria; the trial is sponsored by Wave and run at selected clinical sites in the US.
Can You Buy WVE-007 from a Compounding Pharmacy?
No. WVE-007 is a proprietary, patent-protected molecule manufactured by Wave Life Sciences. It's not on the FDA shortage list, isn't being compounded by 503A or 503B pharmacies, and there's no legitimate source outside the INLIGHT clinical trial.
If you see "WVE-007 for sale" from a peptide vendor, it's almost certainly mislabeled or fake. The chemistry of GalNAc-siRNA conjugates requires specialized RNA synthesis equipment that gray-market peptide manufacturers don't have access to.
WVE-007 Side Effects (Phase 1 So Far)
From the INLIGHT trial through Day 85 of follow-up at the highest dose tested (600 mg), Wave reported:
- No discontinuations from any cohort
- No serious or severe treatment-emergent adverse events
- All treatment-related adverse events were mild
- No clinically meaningful liver function changes (important: the drug acts on the liver, so this was a key safety signal to watch)
- No clinically meaningful lipid panel changes
This is a much cleaner early safety profile than most novel weight-loss drugs at this stage. Whether it holds up at higher cumulative doses and over longer follow-up is the open question for Phase 2.
What This Means for Current GLP-1 Users
If you're on tirzepatide, semaglutide, or another GLP-1 right now, WVE-007 doesn't change your options today, you still can't get it. But the strategic outlook is worth understanding:
- If WVE-007 succeeds in Phase 2-3 trials, the future of obesity treatment likely becomes: aggressive weight loss with a GLP-1, then transition to WVE-007 for muscle-preserving maintenance.
- For now, protect your muscle the proven ways: 1.2-1.6 g protein per kg goal weight daily, resistance training 2-3x per week, slower dose escalation, see our tirzepatide side effects guide for the muscle question in detail.
- Compounded tirzepatide and semaglutide remain the most practical options for weight loss today. Supportive supplements and consistent training will close most of the gap that WVE-007 promises to address.
Frequently Asked Questions
Medical disclaimer: This article is for educational and informational purposes only and is not medical advice. WVE-007 is an investigational drug not approved by the FDA or any other regulatory body. The Phase 1 trial data summarized here is interim and based on a small number of subjects; later-stage trials may produce different results. Do not attempt to source WVE-007 outside an authorized clinical trial. Always talk to a qualified healthcare provider before starting, stopping, or changing any obesity treatment.